LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- iSpecimen
Inc. (Nasdaq: ISPC), an online marketplace for human
biospecimens ("iSpecimen" or the "Company"), today announced
it is expanding its human biospecimen supplier network to offer
increasingly comprehensive selections of whole blood, plasma and
other biofluids to help accelerate the development of liquid
biopsies. In support of this market, the company expanded its
supply network to include another US-based organization with
numerous blood donation centers across the country and access to
tens of thousands of donors registered to provide blood for
research.
A developing technology, liquid biopsies promise to be a less
invasive and more convenient way to detect and help diagnose
various diseases early in their progression when compared to
traditional surgical biopsies. The emerging diagnostic method
typically uses a blood or other biofluid sample – rather than a
tissue sample extracted surgically – to reveal signs of disease,
such as cancer. In the case of liquid biopsies for cancer,
biomarkers may include circulating tumor cells or free-floating DNA
from a tumor.
Researchers hope that liquid biopsies can someday be
administered in a doctor's office and detect cancer or heightened
risk before symptoms appear. Liquid biopsies are also viewed as a
good way to follow the development, recurrence, or mutation of
cancer in individual patients over time. The estimated $1.45 billion global liquid biopsy market is
projected to grow 24% per year through 2026.
Over the past two and a half years, iSpecimen has delivered
thousands of blood, plasma, and other human biofluid samples in
support of nearly 30 mid- and large-size liquid biopsy research and
development studies. More than 100 potential projects were reviewed
for participation during this time, including those with a growing
focus on pan cancer research.
These broader pan cancer research studies aim to detect multiple
cancer types in a liquid biopsy versus a singular result for colon
or prostate cancer, for example, and require extensive access to
human biofluid samples. As a result, research organizations need
more biospecimens from a diverse population of diseased and healthy
donors. An expanding supplier network is an integral part of
growing iSpecimen's liquid biopsy research support
capabilities.
"Liquid biopsy aims to make a significant impact on early cancer
risk assessment, detection, diagnosis, and treatment, which is a
game changer in helping patients live longer, high-quality lives,"
said iSpecimen Founder and CEO, Christopher
Ianelli, MD, Ph.D. "Supporting research and development in
this area is a growing part of iSpecimen's business and embedded in
our mission."
About iSpecimen
iSpecimen offers an online marketplace for human biospecimens,
connecting life scientists in commercial and non-profit
organizations with healthcare providers that have access to
patients and specimens needed for medical discovery. Proprietary,
cloud-based technology enables scientists to intuitively search for
specimens and patients across a federated partner network of
hospitals, labs, biobanks, blood centers, and other healthcare
organizations. For more information about iSpecimen, please visit
www.ispecimen.com.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are characterized by
future or conditional verbs such as "may," "will," "expect,"
"intend," "anticipate," believe," "estimate" and "continue" or
similar words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss / Scott Eckstein
iSpecimen@kcsa.com
Media Contact
Kaitlynn
Cooney
For iSpecimen
kcooney@brodeur.com
617.587.2811
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ispecimen-expands-global-biospecimen-supplier-network-and-access-to-human-biospecimens-needed-to-help-accelerate-development-of-liquid-biopsies-301394586.html
SOURCE iSpecimen Inc.